Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Mithra Pharmaceuticals Sa (1TM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.5140 +0.0120    +2.39%
02:14:30 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  BE0974283153 
S/N:  A14V4E
  • Volume: 0
  • Bid/Ask: 0.5150 / 0.5290
  • Day's Range: 0.5140 - 0.5140
Mithra Pharmaceuticals Sa 0.5140 +0.0120 +2.39%

1TM Balance Sheet

 
Featured here, the Balance Sheet for Mithra Pharmaceuticals Sa, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
30/06
2023
31/03
2022
31/12
2022
30/09
Total Current Assets 92.93 92.93 145.86 145.86
Cash and Short Term Investments 23.71 23.71 28.28 28.28
Cash - - - -
Cash & Equivalents 23.71 23.71 28.28 28.28
Short Term Investments - - - -
Total Receivables, Net 19.56 19.56 61.73 61.73
Accounts Receivables - Trade, Net 19.56 19.56 54.84 54.84
Total Inventory 49.45 49.45 50.31 50.31
Prepaid Expenses - - 4.67 4.67
Other Current Assets, Total 0.201 0.201 0.867 0.867
Total Assets 374.74 374.74 442.41 442.41
Property/Plant/Equipment, Total - Net 102.31 102.31 106.25 106.25
Property/Plant/Equipment, Total - Gross - - 139.18 139.18
Accumulated Depreciation, Total - - -32.93 -32.93
Goodwill, Net 5.23 5.23 5.23 5.23
Intangibles, Net 136.54 136.54 134.9 134.9
Long Term Investments 11.32 11.32 21.44 21.44
Note Receivable - Long Term - - 6.89 6.89
Other Long Term Assets, Total 10.21 10.21 9.54 9.54
Other Assets, Total 46.3 46.3 8.63 8.63
Total Current Liabilities 89.07 89.07 130.43 130.43
Accounts Payable 44.71 44.71 31.72 31.72
Payable/Accrued - - - -
Accrued Expenses - - 7.36 7.36
Notes Payable/Short Term Debt - - 6 6
Current Port. of LT Debt/Capital Leases 42.05 42.05 63.79 63.79
Other Current liabilities, Total 2.31 2.31 21.56 21.56
Total Liabilities 383.47 383.47 408.73 408.73
Total Long Term Debt 264.66 264.66 258.35 258.35
Long Term Debt 230.31 230.31 220.1 220.1
Capital Lease Obligations 34.35 34.35 38.25 38.25
Deferred Income Tax 3.57 3.57 4.42 4.42
Minority Interest - - - -
Other Liabilities, Total 26.17 26.17 -98.04 9.52
Total Equity -8.73 -8.73 33.69 33.69
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 42.89 42.89 41.23 41.23
Additional Paid-In Capital 413.16 413.16 408.65 408.65
Retained Earnings (Accumulated Deficit) -464.76 -464.76 -396.25 -396.25
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -0.021 -0.021 -19.93 -19.93
Total Liabilities & Shareholders' Equity 374.74 374.74 442.41 442.41
Total Common Shares Outstanding 58.59 58.59 56.31 56.31
Total Preferred Shares Outstanding - - - -
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MITRA Comments

Write your thoughts about Mithra Pharmaceuticals SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Muhammad Khawaja
Muhammad Khawaja 7 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mithra got breakthrough wow
Muhammad Khawaja
Muhammad Khawaja Feb 18, 2024 6:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mithra is going to be bankrupt?
Golden Age
Global_K Oct 03, 2023 6:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I can't believe analysts are still giving a 12 month price target of 5.42, this sector is always with great (investor) risks
Jo Vanrutten
Jo Vanrutten Aug 10, 2023 3:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
a lot of potential for the Future
Grégory Vervoort
Grégory Vervoort Aug 12, 2022 4:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mega deal to come with catalent (CTLT) ?
Filip dB
Phildb Aug 10, 2022 3:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
Filip dB
Phildb Aug 01, 2022 3:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
Filip dB
Phildb Jul 26, 2022 2:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NEXSTELLIS® oral contraceptive now available in Australia26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia. NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent. Leon Van Rompay, CEO Mithra Women’s Health
Filip dB
Phildb Jul 01, 2022 7:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 54 million available to Mithra.
Golden Age
Global_K May 06, 2022 5:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1 month later and 8.16, where's the bottom?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email